Panbela Therapeutics (PBLA) Competitors $0.05 0.00 (0.00%) As of 09/12/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PBLA vs. SRNE, LIPO, VRAX, ELAB, CANF, PTIX, GLMD, UPC, VAXX, and ATXIShould you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Sorrento Therapeutics (SRNE), Lipella Pharmaceuticals (LIPO), Virax Biolabs Group (VRAX), PMGC (ELAB), Can-Fite BioPharma (CANF), Atrinsic (PTIX), Galmed Pharmaceuticals (GLMD), Universe Pharmaceuticals (UPC), Vaxxinity (VAXX), and Avenue Therapeutics (ATXI). These companies are all part of the "pharmaceutical products" industry. Panbela Therapeutics vs. Its Competitors Sorrento Therapeutics Lipella Pharmaceuticals Virax Biolabs Group PMGC Can-Fite BioPharma Atrinsic Galmed Pharmaceuticals Universe Pharmaceuticals Vaxxinity Avenue Therapeutics Sorrento Therapeutics (NASDAQ:SRNE) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability. Which has more risk & volatility, SRNE or PBLA? Sorrento Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Which has higher earnings & valuation, SRNE or PBLA? Panbela Therapeutics has lower revenue, but higher earnings than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSorrento Therapeutics$60.32M0.03-$572.84MN/AN/APanbela TherapeuticsN/AN/A-$25.26M-$71.130.00 Do insiders and institutionals have more ownership in SRNE or PBLA? 0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by insiders. Comparatively, 0.0% of Panbela Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor SRNE or PBLA? In the previous week, Sorrento Therapeutics' average media sentiment score of 0.00 equaled Panbela Therapeutics'average media sentiment score. Company Overall Sentiment Sorrento Therapeutics Neutral Panbela Therapeutics Neutral Is SRNE or PBLA more profitable? Company Net Margins Return on Equity Return on Assets Sorrento TherapeuticsN/A N/A N/A Panbela Therapeutics N/A N/A -302.61% SummarySorrento Therapeutics and Panbela Therapeutics tied by winning 3 of the 6 factors compared between the two stocks. Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBLA vs. The Competition Export to ExcelMetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$243K$733.90M$5.79B$10.19BDividend YieldN/A4.84%5.73%4.60%P/E Ratio0.001.1575.4026.02Price / SalesN/A127.38530.60120.19Price / CashN/A19.5625.8129.91Price / Book0.006.6812.166.25Net Income-$25.26M-$4.13M$3.29B$270.76M7 Day PerformanceN/A8.45%0.74%3.87%1 Month PerformanceN/A9.54%5.00%5.49%1 Year PerformanceN/A23.90%62.55%25.86% Panbela Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBLAPanbela Therapeutics0.063 of 5 stars$0.05flatN/AN/A$243KN/A0.006Gap DownSRNESorrento Therapeutics0.9141 of 5 stars$0.01-16.7%N/A-22.2%$2.76M$60.32M0.00800Gap UpLIPOLipella Pharmaceuticals1.9291 of 5 stars$0.59+0.0%N/A-80.2%$2.73M$536.36K-0.144Short Interest ↓VRAXVirax Biolabs Group2.2175 of 5 stars$0.57-5.7%$3.00+425.3%-77.0%$2.63M$10K0.005News CoverageShort Interest ↑Gap DownELABPMGC0.8471 of 5 stars$4.66-17.8%N/A-99.7%$2.41M$1.71M-0.0118Short Interest ↓Gap DownCANFCan-Fite BioPharma1.9043 of 5 stars$0.66+4.9%$14.50+2,089.7%-72.4%$2.34M$674K-0.378Short Interest ↑PTIXAtrinsic0.5335 of 5 stars$3.59-0.3%N/A-70.9%$2.12MN/A-0.272Positive NewsEarnings ReportAnalyst UpgradeShort Interest ↑GLMDGalmed Pharmaceuticals0.9279 of 5 stars$1.27flatN/A-63.3%$2.10MN/A-0.0820Short Interest ↑UPCUniverse Pharmaceuticals0.9514 of 5 stars$3.51-1.1%N/AN/A$2M$23.02M0.00220Short Interest ↓VAXXVaxxinityN/A$0.02-65.9%N/A-95.0%$1.90MN/A-0.0390Gap DownATXIAvenue Therapeutics1.2061 of 5 stars$0.58+1.8%N/A-70.8%$1.85MN/A0.034Gap Up Related Companies and Tools Related Companies Sorrento Therapeutics Competitors Lipella Pharmaceuticals Competitors Virax Biolabs Group Competitors PMGC Competitors Can-Fite BioPharma Competitors Atrinsic Competitors Galmed Pharmaceuticals Competitors Universe Pharmaceuticals Competitors Vaxxinity Competitors Avenue Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBLA) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s right about Epstein.A crisis that could devastate your wealth, upend the dollar, and accelerate the collapse of America’s economy....Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
